UK markets closed

Biotest Aktiengesellschaft (0N6Z.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
33.63+3.83 (+12.85%)
At close: 3:11PM BST
Full screen
Previous close29.80
Open33.69
Bid0.00 x N/A
Ask0.00 x N/A
Day's range33.63 - 33.69
52-week range33.63 - 33.69
Volume5,041
Avg. volumeN/A
Market cap1.211B
Beta (5Y monthly)0.63
PE ratio (TTM)N/A
EPS (TTM)-0.89
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Biotest AG: Biotest successfully completes recruitment for its clinical trial with trimodulin in severe COVID-19 patients

    DGAP-News: Biotest AG / Key word(s): Study02.06.2021 / 07:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest successfully completes recruitment for its clinical trial with trimodulin in severe COVID-19 patients - Trimodulin as potential life-saving treatment for severe COVID-19 patients - All 166 trial patients treated by end of June, first results expected for August 2021- Positive recommendation from Data Safety and Monitoring Board (DSMB) after revie

  • EQS Group

    Biotest AG: Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR)

    Biotest AG / Key word(s): Transaction in Own SharesBiotest AG: Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR)01-Jun-2021 / 12:12 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Ad-hoc RELEASEAnnouncement according to Article 17 European Market Abuse Regulation (MAR)Dreieich, 1 June 2021. Biotest confirms it has been informed by its major shareholder Tiancheng International Investment Limited ("TII") that TII is considering strategic options with regard to its stake in Biotest. Those deliberations are in early stages and may or may not result in a transaction. At this stage, Biotest will refrain from commenting further on the matter.Biotest AktiengesellschaftBoard of ManagementBiotest AGLandsteinerstr. 5D-63303 Dreieichwww.biotest.comDisclaimerThis document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.About BiotestBiotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 1,900 employees worldwide. The preference shares of Biotest AG are listed in the Prime Standard on the Frankfurt stock exchange.IR contactDr. Monika Buttkereitphone: +49-6103-801-4406email: investor_relations@biotest.dePR contactDirk Neumüllerphone: +49-6103-801-269email: pr@biotest.comBiotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.comOrdinary shares: securities' ID No. 522720; ISIN DE0005227201Preference shares: securities' ID No. 522723; ISIN DE0005227235Listing: Frankfurt (Prime Standard)Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, TradegateIR contactDr. Monika Buttkereitphone: +49-6103-801-4406email: investor_relations@biotest.dePR contactDirk Neumüllerphone: +49-6103-801-269email: pr@biotest.comBiotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.comOrdinary shares: securities' ID No. 522720; ISIN DE0005227201Preference shares: securities' ID No. 522723; ISIN DE0005227235Listing: Frankfurt (Prime Standard)Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, TradegateContact:Dr. Michael RamrothChief Financial OfficerBiotest AGLandsteinerstr. 363303 DreieichTel. +40 6103 801 338Fax: +49 6103 801 347Michael.ramroth@biotest.com01-Jun-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1203044 End of Announcement DGAP News Service

  • EQS Group

    Correction of a release from 11/05/2021, 14:30 CET/CEST - Biotest AG: Annual General Meeting approves dividend distribution

    DGAP-News: Biotest AG / Key word(s): AGM/EGM11.05.2021 / 16:45 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest AG: Annual General Meeting approves dividend distribution- Distribution of EUR 0.04 per preferred share- Broad majority on all agenda items in accordance with the proposals of the management (Verwaltung)Dreieich 11 May 2021. At the second ordinary, virtual Annual General Meeting on 11 May 2021, the shareholders of Biotest AG resolved to distribute a dividend. A total of 47.75 % of the share capital was represented. The resolution on the appropriation of the net profit was passed with 99.96% approval for a distribution of € 0.04 per preference share. A total amount of about € 0.8 million will thus be distributed.The shareholders approved the actions of the members of the Executive Board and the Supervisory Board for the 2020 financial year by a large majority. All resolutions on the other items on the agenda were also adopted by a large majority in accordance with the proposals of the management (Verwaltung).The speech of Dr. Michael Ramroth, CEO of Biotest AG, and Dr. Georg Floß, COO of Biotest AG at the Annual General Meeting is available at:https://www.biotest.com/de/en/investor_relations/shareholders_meeting_2021.cfmAbout BiotestBiotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.IR contactDr Monika ButtkereitPhone: +49-6103-801-4406Mail: investor_relations@biotest.dePR contactDirk NeumüllerPhone: +49-6103-801-269Mail: pr@biotest.comBiotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.comOrdinary shares: securities' ID No. 522720; ISIN DE0005227201Preference shares: securities' ID No. 522723; ISIN DE0005227235Listing: Frankfurt (Prime Standard)Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, TradegateDisclaimerThis document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.11.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1195371 End of News DGAP News Service